A5056620057- Renal cell carcinoma treatment
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Tissue Engineering and Regenerative Medicine
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Enzyme function and inhibition
- Immunotherapy and Immune Responses
- Electrospun Nanofibers in Biomedical Applications
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- MRI in cancer diagnosis
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Cancer Research and Treatments
- Urinary and Genital Oncology Studies
- Bone Tissue Engineering Materials
- Medical Imaging Techniques and Applications
- Medical Imaging and Pathology Studies
- 3D Printing in Biomedical Research
- Pelvic floor disorders treatments
- Lymphoma Diagnosis and Treatment
- Urinary Bladder and Prostate Research
Radboud University Nijmegen
2016-2025
Radboud University Medical Center
2016-2025
Radboud Institute for Molecular Life Sciences
2015-2024
University Medical Center
2014-2024
Alfred University
2021
Urology Team
2010
Ziekenhuis Groep Twente
2008
Urology San Antonio
2008
Umeå University
2007
Rijnstate Hospital
2005
Autologous T cells genetically modified to express a chimeric antibody receptor (CAR) against carboxy-anhydrase-IX (CAIX) were administered 12 patients with CAIX-expressing metastatic renal cell carcinoma (RCC). Patients treated in three cohorts maximum of 10 infusions total 0.2 2.1 × 109 CAR cells. CTC grade 2–4 liver enzyme disturbances occurred at the lowest doses, necessitating cessation treatment four out eight 1 and 2. Examination biopsies revealed CAIX expression on bile duct...
Negative costimulation on T cells is exploited by both prostate cancer and melanoma to evade antitumor immunity. Blocking such mechanisms restores immunity as was demonstrated the improved survival of patients with metastatic after treatment an antibody blocking CTLA-4 inhibitory receptor (ipilimumab). Enhanced expression another immunoreceptor, programmed death-1 (PD-1), its ligand, PD-L1, found correlate a poor prognosis in melanoma. PD-1-blocking antibodies are being developed modulate...
The anti-tuberculosis-vaccine Bacillus Calmette-Guérin (BCG) is the most widely used vaccine in world. In addition to its effects against tuberculosis, BCG vaccination also induces non-specific beneficial certain forms of malignancy and infections with unrelated pathogens. It has been recently proposed that are mediated through epigenetic reprogramming monocytes, a process called trained immunity. present study we demonstrate autophagy contributes immunity induced by BCG. Pharmacologic...
PURPOSE To define the imaging and biodistribution characteristics of iodine 131-labeled monoclonal antibody (mAb) G250 (131I-mAbG250), which recognizes a cell-surface antigen expressed by human renal cell carcinoma (RCC). PATIENTS AND METHODS is recognized mAbG250 RCC but not detected in normal kidney. Clear-cell RCC, most frequent form shows homogeneous expression G250, whereas non-clear-cell cancers derived from other organs generally do express G250. Expression tissues highly restricted...
Intraoperative imaging with antibodies labeled both a radionuclide for initial guidance and near-infrared dye adequate tumor delineation may overcome the main limitation of fluorescence imaging: limited penetration depth light in biological tissue.In this study, we demonstrate feasibility safety intraoperative dual-modality carbonic anhydrase IX (CAIX)targeting antibody 111 In-DOTA-girentuximab-IRDye800CW clear cell renal carcinoma (ccRCC) patients.Methods: A phase I protein dose escalation...
One of the promises synthetic materials in cell culturing is that control over their molecular structures may ultimately be used to biological processes. Synthetic polymer hydrogels from polyisocyanides (PIC) are a new class minimal biomaterials for three-dimensional culturing. The macromolecular lengths and densities biofunctional groups decorate can readily manipulated while preserving intrinsic nonlinear mechanics, feature commonly displayed by fibrous networks. In this work, we propose...
BCG is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it unknown whether application induces trained immunity.The aim this research was determine immunity NMIBC patients. We conducted a prospective observational cohort study 17 scheduled for therapy and measured parameters at 9 time points before during 1-year maintenance regimen. Ex vivo cytokine production by peripheral blood...
Cells continuously sense external forces from their microenvironment, the extracellular matrix (ECM). In turn, they generate contractile forces, which stiffen and remodel this matrix. Although bidirectional mechanical exchange is crucial for many cell functions, it remains poorly understood. Key challenges are that majority of available matrices such studies, either natural or synthetic, difficult to control lack biological relevance. Here, we use a yet highly biomimetic hydrogel based on...
The molecular cloning of the cDNA and gene encoding renal cell carcinoma (RCC)-associated protein G250 is described. This one best markers for clear RCC: all clear-cell RCC express this protein, whereas no expression can be detected in normal kidney most other tissue. Antibody studies have indicated that molecule might serve as a therapeutic target. In view induction/up-regulation antigen RCC, its restricted tissue possible role therapy, we set out to molecularly define antigen, which...
Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal carcinoma (RCC). A multicentre phase II study was performed evaluate the safety and efficacy WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. given weekly by intravenous infusion for 12 weeks. Patients stable disease (SD) or response eligible receive additional treatment 8 None enrolled experienced any drug-related grade III IV toxicity. Only three had...
The monoclonal antibody G250 (mAbG250) raised against a human renal cell carcinoma (RCC) has been shown to react with large number of RCCs. Recently, antigen was isolated and found be homologous the MN/CA9 gene originally identified in HeLa cells. To determine whether (MN/CA IX/G250) could potential therapeutic target tumour marker, total 147 cases RCC were investigated immunohistochemically as well by reverse transcriptase polymerase chain reaction (RT-PCR) analysis. In addition, RNAs...
PURPOSE Pharmacokinetics, biodistribution, immunogenicity, and imaging characteristics of iodine 131 (131I)-labeled chimeric monoclonal antibody (mAb) G250 (cG250) were studied in patients with renal cell carcinoma (RCC) to determine the therapeutic potential this antibody. PATIENTS AND METHODS Sixteen RCC received a single intravenous (IV) infusion 6 mCi 131I-labeled cG250. Five protein dose levels investigated (2 50 mg). Planar scintigraphic images acquired, normal tissue biopsies tumor...